183 related articles for article (PubMed ID: 12213398)
1. Recombinant vaccine against hepatitis E: duration of protective immunity in rhesus macaques.
Zhang M; Emerson SU; Nguyen H; Engle R; Govindarajan S; Blackwelder WC; Gerin J; Purcell RH
Vaccine; 2002 Sep; 20(27-28):3285-91. PubMed ID: 12213398
[TBL] [Abstract][Full Text] [Related]
2. Immunogenicity and protective efficacy of a vaccine prepared from 53 kDa truncated hepatitis E virus capsid protein expressed in insect cells.
Zhang M; Emerson SU; Nguyen H; Engle RE; Govindarajan S; Gerin JL; Purcell RH
Vaccine; 2001 Dec; 20(5-6):853-7. PubMed ID: 11738749
[TBL] [Abstract][Full Text] [Related]
3. Pre-clinical immunogenicity and efficacy trial of a recombinant hepatitis E vaccine.
Purcell RH; Nguyen H; Shapiro M; Engle RE; Govindarajan S; Blackwelder WC; Wong DC; Prieels JP; Emerson SU
Vaccine; 2003 Jun; 21(19-20):2607-15. PubMed ID: 12744897
[TBL] [Abstract][Full Text] [Related]
4. Immunogenicity and protective efficacy in rhesus monkeys of a recombinant ORF2 protein from hepatitis E virus genotype 4.
Huang WJ; Zhang HY; Harrison TJ; Lan HY; Huang GY; Wang YC
Arch Virol; 2009; 154(3):481-8. PubMed ID: 19240977
[TBL] [Abstract][Full Text] [Related]
5. Recombinant vaccine against hepatitis E: dose response and protection against heterologous challenge.
Tsarev SA; Tsareva TS; Emerson SU; Govindarajan S; Shapiro M; Gerin JL; Purcell RH
Vaccine; 1997 Dec; 15(17-18):1834-8. PubMed ID: 9413090
[TBL] [Abstract][Full Text] [Related]
6. Assessment of the cross-protective capability of recombinant capsid proteins derived from pig, rat, and avian hepatitis E viruses (HEV) against challenge with a genotype 3 HEV in pigs.
Sanford BJ; Opriessnig T; Kenney SP; Dryman BA; Córdoba L; Meng XJ
Vaccine; 2012 Sep; 30(44):6249-55. PubMed ID: 22906724
[TBL] [Abstract][Full Text] [Related]
7. Challenge studies in Rhesus monkeys immunized with candidate hepatitis E vaccines: DNA, DNA-prime-protein-boost and DNA-protein encapsulated in liposomes.
Arankalle VA; Lole KS; Deshmukh TM; Srivastava S; Shaligram US
Vaccine; 2009 Feb; 27(7):1032-9. PubMed ID: 19095027
[TBL] [Abstract][Full Text] [Related]
8. A truncated ORF2 protein contains the most immunogenic site on ORF2: antibody responses to non-vaccine sequences following challenge of vaccinated and non-vaccinated macaques with hepatitis E virus.
Zhou YH; Purcell RH; Emerson SU
Vaccine; 2005 May; 23(24):3157-65. PubMed ID: 15837215
[TBL] [Abstract][Full Text] [Related]
9. [Vaccination of rhesus monkeys with recombinant antigen fragments and protection from hepatitis E virus infection].
Ma YB; Xie TH; Zhang GM; Li CH; Dai XJ; Dai CB; Sun MS; Lu J; Bi SL
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2002 Dec; 24(6):592-5. PubMed ID: 12905686
[TBL] [Abstract][Full Text] [Related]
10. Preliminary evidence that a trpE-HEV fusion protein protects cynomolgus macaques against challenge with wild-type hepatitis E virus (HEV).
Purdy MA; McCaustland KA; Krawczynski K; Spelbring J; Reyes GR; Bradley DW
J Med Virol; 1993 Sep; 41(1):90-4. PubMed ID: 8228944
[TBL] [Abstract][Full Text] [Related]
11. A bacterially expressed particulate hepatitis E vaccine: antigenicity, immunogenicity and protectivity on primates.
Li SW; Zhang J; Li YM; Ou SH; Huang GY; He ZQ; Ge SX; Xian YL; Pang SQ; Ng MH; Xia NS
Vaccine; 2005 Apr; 23(22):2893-901. PubMed ID: 15780738
[TBL] [Abstract][Full Text] [Related]
12. Multimodal investigation of rat hepatitis E virus antigenicity: Implications for infection, diagnostics, and vaccine efficacy.
Sridhar S; Situ J; Cai JP; Yip CC; Wu S; Zhang AJ; Wen L; Chew NF; Chan WM; Poon RW; Chan JF; Tsang DN; Chen H; Xia NS; Yuen KY
J Hepatol; 2021 Jun; 74(6):1315-1324. PubMed ID: 33845058
[TBL] [Abstract][Full Text] [Related]
13. Protective efficacy of hepatitis E virus DNA vaccine administered by gene gun in the cynomolgus macaque model of infection.
Kamili S; Spelbring J; Carson D; Krawczynski K
J Infect Dis; 2004 Jan; 189(2):258-64. PubMed ID: 14722891
[TBL] [Abstract][Full Text] [Related]
14. Cross-protection of hepatitis E virus genotypes 1 and 4 in rhesus macaques.
Huang W; Zhang H; Harrison TJ; Lang S; Huang G; Wang Y
J Med Virol; 2008 May; 80(5):824-32. PubMed ID: 18360896
[TBL] [Abstract][Full Text] [Related]
15. Immunogenicity and efficacy of a bacterially expressed HEV ORF3 peptide, assessed by experimental infection of primates.
Ma H; Song X; Harrison TJ; Li R; Huang G; Zhang H; Kong W; Wang Y
Arch Virol; 2009; 154(10):1641-8. PubMed ID: 19763777
[TBL] [Abstract][Full Text] [Related]
16. Induction of antibody response against hepatitis E virus (HEV) with recombinant human papillomavirus pseudoviruses expressing truncated HEV capsid proteins in mice.
Renoux VM; Fleury MJ; Bousarghin L; Gaitan J; Sizaret PY; Touzé A; Coursaget P
Vaccine; 2008 Dec; 26(51):6602-7. PubMed ID: 18835319
[TBL] [Abstract][Full Text] [Related]
17. Toward the development of a hepatitis E vaccine.
Kamili S
Virus Res; 2011 Oct; 161(1):93-100. PubMed ID: 21620908
[TBL] [Abstract][Full Text] [Related]
18. DNA vaccination against hepatitis E virus infection in cynomolgus macaques.
Kamili S; Spelbring J; Krawczynski K
J Gastroenterol Hepatol; 2002 Dec; 17 Suppl 3():S365-9. PubMed ID: 12472965
[TBL] [Abstract][Full Text] [Related]
19. Use of a Recombinant Gamma-2 Herpesvirus Vaccine Vector against Dengue Virus in Rhesus Monkeys.
Bischof GF; Magnani DM; Ricciardi M; Shin YC; Domingues A; Bailey VK; Gonzalez-Nieto L; Rakasz EG; Watkins DI; Desrosiers RC
J Virol; 2017 Aug; 91(16):. PubMed ID: 28592531
[TBL] [Abstract][Full Text] [Related]
20. Progress in the Production of Virus-Like Particles for Vaccination against Hepatitis E Virus.
Mazalovska M; Kouokam JC
Viruses; 2020 Jul; 12(8):. PubMed ID: 32751441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
